Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India Business Makes Gains At Glenmark While Rest Of World Sees Mixed Results

Plus Firm Settles With Pfizer On Generic Axitinib

Executive Summary

Glenmark’s domestic business was seen to gradually strengthen its market share during Q2, while its North American division saw a minor decline in growth and a drop in COVID-related sales took its toll.

You may also be interested in...



Hikma And Glenmark Launch Ryaltris In US

Hikma and Glenmark have announced the long-awaited launch of the Ryaltris nasal spray on which the two companies have partnered in the US.

Tough Q1 In US For Glenmark, Eyes on Ryaltris Debut, Flovent Rival Filing

Glenmark signals “very challenging” US environment but expects things to stabilize with a string of potential new launches in the wings. The impending debut of Ryaltris, among other products, and a filing for a generic rival to Flovent could add some spark to the US business.

Nichi-Iko Set To Delist In March As Tamura Steps Down As CEO

After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel